WO2007003982A1 - Improved process for the manufacture of flecainide - Google Patents
Improved process for the manufacture of flecainide Download PDFInfo
- Publication number
- WO2007003982A1 WO2007003982A1 PCT/IB2005/002682 IB2005002682W WO2007003982A1 WO 2007003982 A1 WO2007003982 A1 WO 2007003982A1 IB 2005002682 W IB2005002682 W IB 2005002682W WO 2007003982 A1 WO2007003982 A1 WO 2007003982A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- bis
- compound
- trifluoroethoxy
- chloride
- Prior art date
Links
- RXCBHSJSTYMELN-UHFFFAOYSA-N O=C(c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F)OCC(F)(F)F Chemical compound O=C(c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F)OCC(F)(F)F RXCBHSJSTYMELN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
Definitions
- the present invention relates to an improved process for the manufacture of N-(pyridin-2- ylmethyl) 2,5-bis(2,2,2-trifiuoroethoxy)benzamide II, which is the penultimate intermediate in the manufacture of ⁇ -(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide acetate (flecainide acetate) of the formula I.
- Flecainide acetate (I) is a widely used class Ic antiarrhythmic agent. It is indicated for various types of arrhythmias. It is used to regulate the rate and rhythm of the heart. The heart's pumping action is controlled by electrical signals that pass through the heart muscle. The electrical signals cause the two pairs of heart chambers (left and right arteria and ventricles) to contract in a regular manner to produce regular heartbeats. If the electrical activity in the heart is disturbed for any reason, irregular heartbeats (arrhythmias) of various types can result. These can seriously undermine the pumping action of the heart and result in inefficient blood circulation around the body. Flecainide helps to treat arrhythmias by decreasing the sensitivity of the heart muscle cells to electrical impulses. This regulates the electrical conduction in the heart muscle and reduces disturbances in the heart rhythm. Several processes for the manufacture of the same are reported.
- the United States Patent No. 3,900,481 relates to the manufacture of certain compounds in which a carbon atom of a pyrrolidine or piperidine is bonded directly or through a methylene group to the nitrogen of a substituted benzamido group and their pharmaceutically acceptable salts are active as antiarrhythmic agents.
- This process utilizes hazardous chemicals and intermediates, which are commercially not available from multiple sources and is hence not of commercial importance. Besides this process gives the compound in low purities due to coupling occurring at the piperidinyl nitrogen and is hence not economical and commercially viable.
- the US patent 4,642,384 relates to processes for the preparation of intermediates such as 2,5- bis(2,2,2-trifluoroethoxy)acetophenone, 2,5-bis(2,2,2-trifluoroethoxy) ⁇ , ⁇ - dichloroacetophenone, 2,5-bis(2,2,2-trifluoroethoxy) ⁇ , ⁇ , ⁇ -trichloroacetophenone and subsequent condensation with 2-aminomethylpyridine followed by catalytic hydrogenation to afford Flecainide acetate of the formula I.
- This process is again not advantageous on an industrial scale.
- the patent US 6,316,627 provides with a process for preparation of the title compound characterized in that the product namely, 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid was reacted with XCH 2 CN to form a cyanomethyl ester derivative (VII) and was converted to flecainide by reacting with RCH 2 NH 2 (where R denotes pyridyl group) followed by catalytic hydrogenation.
- RCH 2 NH 2 where R denotes pyridyl group
- the patent US 6.458,957 related to the use of o ⁇ a-dibromo-a-chloroacetophenone compounds (VIII), more particularly 2,5-bis(2,2,2-trifluoroethoxy)- ⁇ , ⁇ -dibromo- ⁇ - chloroacetophenone as intermediates for preparing Flecainide.
- the process comprises of converting the ⁇ -chloro acetophenone to an ⁇ , ⁇ -dibromo- ⁇ -chloroacetophenone derivative and reacting the same with a primary or secondary amine.
- the process is further characterized in that when the amine is 2-(aminomethyl)pyridine it forms 2,5 ⁇ bis(2,2,2 trifluoroethoxy)-N-(2-pyridylmethyl)benzamide and reducing the same with hydrogen affords 2,5-bis(2,2,2 trifluoroethoxy)-N-(2-piperidylmethyl)benzamide.
- This process involves bromination and is hence unsatisfactory from an ecological point of view.
- the patent US 6.599,992 relates to a process for the preparation of flecainide comprising of synthesis of the key intermediate 2',2',2'-trifluoroethanol 2,5-bis-(2,2,2- trifluooroethoxy)benzoate (IX), by reaction of 2,5-dihydroxy benzoic acid with 2,2,2- trifluoroethanol perfluorobutanesulphonate in presence of organic bases.
- This intermediate on subsequent reaction with 2-aminomethylpiperidine gave flecainide.
- This process again utilizes the costly trifluoroethanol as a leaving group and is hence economically unviable.
- the Spanish patent ES 2007,02 relates to a process for the manufacture of Flecainide comprising of reacting an activated derivative (X) of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid (X) with 2-azaindolizidine, which is selectively hydrolyzed to flecainide followed by salification with glacial acetic acid.
- This route again employs a costly chemical for activation and hence not feasible on a commercial scale.
- An object of the invention is to provide a process for the transformation from a compound of the formula X to a compound of the formula II and thereby to the compound of the formula I in high yields and purities.
- Another object of the present invention is to provide a process for the manufacture of the compound of the formula II that is simple, easy and convenient to carry out.
- Another object of the invention is to provide a process for the manufacture of the compound of the formula II that is economical and commercially viable.
- the intermediate can then be subjected to catalytic hydrogenation for the reduction of the pyridyl group to afford flecainide, which is isolated as the acetate.
- N-(pyridin-2- ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide (II) consisting of reacting 2,5-bis (2,2,2- trifluoroethoxy) benzoic acid of the formula VI with an acid chloride of the formula R 1 COCl wherein Rl is ethyl, tertiary butyl, or ethoxy in a suitable solvent mixture in the presence of a base at -10 to -50 0 C to obtain a mixed anhydride of the formula (XI)
- Rl is as defined above which is then condensed with a solution of 2-aminomethyl pyridine at -10 to -4O 0 C followed by hydrolytic workup and extraction of the product and isolation by distillation of the extracting solvent.
- methyl chloroformate ethyl chloroformate
- trimethyl acetyl chloride preferably pivaloyl chloride
- tertiary amines such as triethyl amine, pyridine, lutidine or ⁇ - methyl morpholine preferably triethyl amine.
- the suitable solvent mixture comprises a halogenated hydrocarbon solvent such as methylene chloride, chloroform or ethylene chloride preferably methylene chloride and a polar aprotic solvent selected from the group comprising ⁇ , ⁇ -dimethyl formamide, N,N-dimethyl acetamide, N,N-dimethyl sulfoxide or N-methyl-2-pyrrolidone preferably N,N-dimethyl acetamide.
- the halogenated hydrocarbon solvent and polar aprotic solvent are preferably in the ratio 3:1.
- the base used for the mixed anhydride formation is employed in the molar ratio from 1:0.9 to 1:1.5 with respect to the compound of the formula VI preferably 1:1.05.
- the temperature during the mixed anhydride stage is in the range from -10 to -50 0 C preferably -20 0 C.
- condensation reaction of the mixed anhydride with 2-aminomethyl pyridine is conducted from -10 to - 40 0 C, preferably about -20 0 C.
- the process of the invention does not use any corrosive chemical.
- the condensation reaction between the mixed anhydride and 2-aminomethyl pyridine is practically quantitative and affords the compound of the formula II in high yields ( ⁇ 95%) and high purities (-99%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
The invention describes an improved process for the manufacture of a Flecainide intermediate viz N-(pyridin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide (II). It consists of reacting 2,5-bis (2,2,2-trifluoroethoxy) benzoic acid with an acid chloride in a solvent mixture in presence of a base at -10 to -50°C. The resulting mixed anhydride is then condensed with 2-aminomethylpyridine at -10 to -40°C and the resulting product after aqueous workup is purified by crystallization. This affords the intermediate II in vastly improved yields and quality. The intermediate II on catalytic hydrogenation affords N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide (Flecainide), isolated as its acetate.
Description
IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE
BACKGROUND OF THE INVENTION
The present invention relates to an improved process for the manufacture of N-(pyridin-2- ylmethyl) 2,5-bis(2,2,2-trifiuoroethoxy)benzamide II, which is the penultimate intermediate in the manufacture of Ν-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide acetate (flecainide acetate) of the formula I.
Flecainide acetate (I) is a widely used class Ic antiarrhythmic agent. It is indicated for various types of arrhythmias. It is used to regulate the rate and rhythm of the heart. The heart's pumping action is controlled by electrical signals that pass through the heart muscle. The electrical signals cause the two pairs of heart chambers (left and right arteria and ventricles) to contract in a regular manner to produce regular heartbeats. If the electrical activity in the heart is disturbed for any reason, irregular heartbeats (arrhythmias) of various types can result. These can seriously undermine the pumping action of the heart and result in inefficient blood circulation around the body. Flecainide helps to treat arrhythmias by decreasing the sensitivity of the heart muscle cells to electrical impulses. This regulates the electrical conduction in the heart muscle and reduces disturbances in the heart rhythm. Several processes for the manufacture of the same are reported.
A key intermediate in the synthesis of the compound of the formula I is the compound of the formula II. This intermediate is also the object of the invention of several earlier patents.
PRIOR ART
The United States Patent No. 3,900,481 relates to the manufacture of certain compounds in which a carbon atom of a pyrrolidine or piperidine is bonded directly or through a methylene group to the nitrogen of a substituted benzamido group and their pharmaceutically acceptable salts are active as antiarrhythmic agents.
Herein, fiecanide was prepared by converting 1,4-R2C6H4 (R= halogen, OH) into 1,4- (F3CCH2O)2C6H4 (III), which was acetylated to give 2,5-(F3CCH2O)2C6H3COMe (IV), which was then chlorinated to give 2,5-(F3CCH2O)2C6H3COCCl3 (V), which was finally hydrolyzed to (F3CCH2O)2C6HsCO2H (VI) and was converted to acid chloride followed by reaction with 2-aminomethylpiperidine to give I. This process utilizes hazardous chemicals and
intermediates, which are commercially not available from multiple sources and is hence not of commercial importance. Besides this process gives the compound in low purities due to coupling occurring at the piperidinyl nitrogen and is hence not economical and commercially viable.
The US patents 4,097,481 and US 4,617,396 deal with tertiary amide derivatives of pyrrolidine and piperidine and process for their preparation but essentially having a similar strategy for amidification as described for US 3,900,481. These processes suffer similarly as detailed above.
The US patent 4,642,384 relates to processes for the preparation of intermediates such as 2,5- bis(2,2,2-trifluoroethoxy)acetophenone, 2,5-bis(2,2,2-trifluoroethoxy)α,α- dichloroacetophenone, 2,5-bis(2,2,2-trifluoroethoxy)α,α,α-trichloroacetophenone and subsequent condensation with 2-aminomethylpyridine followed by catalytic hydrogenation to afford Flecainide acetate of the formula I. This process is again not advantageous on an industrial scale.
The patent US 6,316,627 provides with a process for preparation of the title compound characterized in that the product namely, 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid was reacted with XCH2CN to form a cyanomethyl ester derivative (VII) and was converted to flecainide by reacting with RCH2NH2 (where R denotes pyridyl group) followed by catalytic hydrogenation. This patent makes use of expensive haloalkyl nitriles for forming the intermediate and is thus far from satisfactory.
The patent US 6.458,957 related to the use of o^a-dibromo-a-chloroacetophenone compounds (VIII), more particularly 2,5-bis(2,2,2-trifluoroethoxy)-α,α-dibromo-α- chloroacetophenone as intermediates for preparing Flecainide. The process comprises of converting the α-chloro acetophenone to an α,α-dibromo-α-chloroacetophenone derivative and reacting the same with a primary or secondary amine. The process is further characterized in that when the amine is 2-(aminomethyl)pyridine it forms 2,5~bis(2,2,2 trifluoroethoxy)-N-(2-pyridylmethyl)benzamide and reducing the same with hydrogen affords 2,5-bis(2,2,2 trifluoroethoxy)-N-(2-piperidylmethyl)benzamide. This process involves bromination and is hence unsatisfactory from an ecological point of view.
The patent US 6.599,992 relates to a process for the preparation of flecainide comprising of synthesis of the key intermediate 2',2',2'-trifluoroethanol 2,5-bis-(2,2,2- trifluooroethoxy)benzoate (IX), by reaction of 2,5-dihydroxy benzoic acid with 2,2,2- trifluoroethanol perfluorobutanesulphonate in presence of organic bases. This intermediate on
subsequent reaction with 2-aminomethylpiperidine gave flecainide. This process again utilizes the costly trifluoroethanol as a leaving group and is hence economically unviable.
The Spanish patent ES 2007,02 relates to a process for the manufacture of Flecainide comprising of reacting an activated derivative (X) of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid (X) with 2-azaindolizidine, which is selectively hydrolyzed to flecainide followed by salification with glacial acetic acid. This route again employs a costly chemical for activation and hence not feasible on a commercial scale. SUMMARY OF THE INVENTION
An object of the invention is to provide a process for the transformation from a compound of the formula X to a compound of the formula II and thereby to the compound of the formula I in high yields and purities.
Another object of the present invention is to provide a process for the manufacture of the compound of the formula II that is simple, easy and convenient to carry out.
Another object of the invention is to provide a process for the manufacture of the compound of the formula II that is economical and commercially viable. The intermediate can then be subjected to catalytic hydrogenation for the reduction of the pyridyl group to afford flecainide, which is isolated as the acetate.
DETAILED DESCRIPTION
According to the invention there is provided a process for the manufacture of N-(pyridin-2- ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide (II) consisting of reacting 2,5-bis (2,2,2- trifluoroethoxy) benzoic acid of the formula VI with an acid chloride of the formula R1COCl wherein Rl is ethyl, tertiary butyl, or ethoxy in a suitable solvent mixture in the presence of a base at -10 to -500C to obtain a mixed anhydride of the formula (XI)
wherein Rl is as defined above which is then condensed with a solution of 2-aminomethyl pyridine at -10 to -4O0C followed by hydrolytic workup and extraction of the product and isolation by distillation of the extracting solvent.
As an acid chloride one can utilize methyl chloroformate, ethyl chloroformate, or trimethyl acetyl chloride (pivaloyl chloride) preferably pivaloyl chloride.
As a base one can utilize the tertiary amines such as triethyl amine, pyridine, lutidine or Ν- methyl morpholine preferably triethyl amine.
The suitable solvent mixture comprises a halogenated hydrocarbon solvent such as methylene chloride, chloroform or ethylene chloride preferably methylene chloride and a polar aprotic solvent selected from the group comprising Ν,Ν-dimethyl formamide, N,N-dimethyl acetamide, N,N-dimethyl sulfoxide or N-methyl-2-pyrrolidone preferably N,N-dimethyl acetamide. The halogenated hydrocarbon solvent and polar aprotic solvent are preferably in the ratio 3:1.
The base used for the mixed anhydride formation is employed in the molar ratio from 1:0.9 to 1:1.5 with respect to the compound of the formula VI preferably 1:1.05.
The temperature during the mixed anhydride stage is in the range from -10 to -500C preferably -200C.
Typically the condensation reaction of the mixed anhydride with 2-aminomethyl pyridine is conducted from -10 to - 400C, preferably about -200C.
The process of the invention does not use any corrosive chemical. The condensation reaction between the mixed anhydride and 2-aminomethyl pyridine is practically quantitative and affords the compound of the formula II in high yields (~95%) and high purities (-99%).
Therefore the process of the invention is simple, easy, convenient and fast to carry out. For these reasons the process is. economical and commercially viable.
The following examples are illustrative of the invention but not restricted to the scope thereof.
EXAMPLE-I
60 gm of 2,5-bis (2,2,2-trifluoroethoxy) benzoic acid was suspended in a mixture of 480 ml methylene chloride and 90 ml N,N-dimethyl acetamide. To this 22.9 gm of triethyl amine was added and the mixture was cooled to -3O0C. To this 27.4 gm of pivaloyl chloride and the mass stirred at -20 to -300C. A solution of 21.6 gm of 2-aminomethyl pyridine in 120 ml of methylene chloride was added and the mixture was maintained at -2O0C for 120 min. The reaction mixture was quenched in 780 ml of water. After 30 min the lower organic layer was separated and washed with 300 ml 5% sodium carbonate solution. The organic layer was filtered and distilled. The residue was diluted with 360 ml cyclohexane and filtered. The solid was washed with 100 ml cyclohexane and dried at 400C under vacuum to give 72 gm of N- (pyridin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide.
Water (by Karl Fisher)=0.23%. HPLC assay=99.2%. (Theoretical =75 gm)
EXAMPLE-2
The procedure of example 1 was followed with 26 gm of N-methyl morpholine instead of triethyl amine and the isolated product dried at 40°C under vacuum to give 71 gm of N- (pyridin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide.
Water (by Karl Fisher)=0.18%. HPLC assay=99.1%. (Theoretical =75 gm)
EXAMPLE-3
The procedure of example 1 was followed with 24.7 gm of ethyl chloro formate instead of pivaloyl chloride and the isolated product dried at 4O0C under vacuum to give 71.5 gm of N- (pyridin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide.
Water (by Karl Fisher)=0.26%. HPLC assay=99.0%. (Theoretical =75 gm)
EXAMPLE-4
The procedure of example 1 was followed with 90 ml of Ν,Ν-dimethyl formamide instead of N,N-dimethyl acetamide and the isolated product dried at 4O0C under vacuum to give 70.8 gm of N-(pyridin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide. Water (by Karl Fisher)=0.29%. HPLC assay=99.1%. (Theoretical =75 gm)
Claims
1. A process for the manufacture of N-(pyridin-2-ylmethyl)-2,5-bis(2,2,2- trifluoroethoxy) benzamide of the formula II,
comprising of reacting 2,5-bis(2,2,2-trifluoroethoxy) benzoic acid of the formula VI with an acid chloride of the formula R1COCl wherein R1 is methyl, ethyl, t-butyl or ethoxy in a solvent mixture, in the presence of a base at -10 to -500C to obtain a mixed anhydride of the formula XI
where Ri is methyl, ethyl, t-butyl or ethoxy, the mixed anhydride is then condensed with a solution of 2-aminomethyl pyridine at -10 to -400C and subsequently subjected to hydrolytic workup and extraction followed by distillation of the solvent to afford the desired compound of the formula II. The compound of the formula II is then converted to a compound of the formula I by catalytic hydrogenation.
2. A process as claimed in claim 1, wherein the acid chloride can be selected from among the group comprising of methyl chloroformate, ethyl chloroformate, or
trimethyl acetyl chloride (pivaloyl chloride) but preferably pivaloyl chloride and the solvent mixture comprises methylene chloride and N,N-dimethyl acetamide.
3. A process as claimed in claim 1, wherein the solvent mixture comprises of a halogenated hydrocarbon solvent such as methylene chloride, chloroform or ethylene chloride preferably methylene chloride and a polar aprotic solvent selected from the group comprising N,N-dimethyl formamide, N,N-dimethyl acetamide, N,N-dimethyl sulfoxide or N-methyl-2-pyrrolidone preferably N,N-dimethyl acetamide.
4. A process as claimed in claim 1, wherein the base can be selected from the group comprising of tertiary amines such as triethyl amine, pyridine, lutidine or N-methyl morpholine preferably triethyl amine.
5. A process as claimed in claim 1, wherein the temperature during the mixed anhydride stage is in the range from -10 to -500C preferably -200C.
6. A process as claimed in claim 1, wherein the temperature during the condensation stage is in the range from -10 to -400C preferably -200C.
7. A process as claimed in claim 4, wherein the solvent ratio of the halogenated hydrocarbon to the polar aprotic solvent ranges from 1:5 to 1:10 preferably 1:6.
8. The base used for the mixed anhydride formation is employed in the molar ratio from 1:0.9 to 1:1.5 with respect to the compound of the formula VI preferably 1:1.05.
9. A process as claimed in claim 4, wherein the compound of the formula II is converted to a compound of the formula I by catalytic hydrogenation.
10. A process for the manufacture of N-(pyridin-2-ylmethyl)-2,5-bis(2,2,2- trifluoroethoxy) benzamide of the formula II and the base used for the mixed anhydride formation substantially as hereindescribed with reference to the given specification.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05783707A EP1907360B1 (en) | 2005-07-04 | 2005-09-09 | Improved process for the manufacture of flecainide |
DE602005027261T DE602005027261D1 (en) | 2005-07-04 | 2005-09-09 | IMPROVED METHOD FOR THE PRODUCTION OF FLECAINIDE |
US11/988,126 US20100184990A1 (en) | 2005-07-04 | 2005-09-09 | Process for the Manufacture of Flecainide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN789MU2005 | 2005-07-04 | ||
IN789/MUM/2005 | 2005-07-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007003982A1 true WO2007003982A1 (en) | 2007-01-11 |
Family
ID=37604122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/002682 WO2007003982A1 (en) | 2005-07-04 | 2005-09-09 | Improved process for the manufacture of flecainide |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100184990A1 (en) |
EP (1) | EP1907360B1 (en) |
DE (1) | DE602005027261D1 (en) |
WO (1) | WO2007003982A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102918397A (en) * | 2010-04-01 | 2013-02-06 | 班扬生物标记公司 | Markers and assays for detection of neurotoxicity |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109425666B (en) * | 2017-08-28 | 2022-07-08 | 广东东阳光药业有限公司 | LC-MS analysis method of acyl chloride derivative |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002498A1 (en) * | 1997-07-11 | 1999-01-21 | Finetech Ltd. | Process and a novel intermediate for the preparation of flecainide |
WO2002004419A2 (en) * | 2000-07-12 | 2002-01-17 | Geneva Pharmaceuticals, Inc. | α,α-DIBROMO-α-CHLORO-ACETOPHENONES AS SYNTHONS |
WO2002066413A1 (en) * | 2001-02-20 | 2002-08-29 | Narchem Corporation | Flecainide synthesis |
-
2005
- 2005-09-09 DE DE602005027261T patent/DE602005027261D1/en active Active
- 2005-09-09 US US11/988,126 patent/US20100184990A1/en not_active Abandoned
- 2005-09-09 EP EP05783707A patent/EP1907360B1/en not_active Not-in-force
- 2005-09-09 WO PCT/IB2005/002682 patent/WO2007003982A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002498A1 (en) * | 1997-07-11 | 1999-01-21 | Finetech Ltd. | Process and a novel intermediate for the preparation of flecainide |
WO2002004419A2 (en) * | 2000-07-12 | 2002-01-17 | Geneva Pharmaceuticals, Inc. | α,α-DIBROMO-α-CHLORO-ACETOPHENONES AS SYNTHONS |
WO2002066413A1 (en) * | 2001-02-20 | 2002-08-29 | Narchem Corporation | Flecainide synthesis |
Non-Patent Citations (2)
Title |
---|
BANITT E.H. ET AL.: "Antiarrhythmics. 2. Synthesis and Antiarrhythmic Activity of N-(Piperidylalkyl)trifluoroethoxybenzamides", JOURNAL OF MEDICINAL CHEMISTRY, vol. 20, no. 6, 1977, pages 821 - 826, XP002215769 * |
See also references of EP1907360A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102918397A (en) * | 2010-04-01 | 2013-02-06 | 班扬生物标记公司 | Markers and assays for detection of neurotoxicity |
Also Published As
Publication number | Publication date |
---|---|
EP1907360A1 (en) | 2008-04-09 |
EP1907360B1 (en) | 2011-03-30 |
US20100184990A1 (en) | 2010-07-22 |
EP1907360A4 (en) | 2009-04-01 |
DE602005027261D1 (en) | 2011-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005289099B2 (en) | Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide | |
WO2014192030A2 (en) | An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof | |
WO2014009966A2 (en) | An improved process for the preparation of dabigatran etexilate mesylate and its intermediates thereof | |
US9533971B2 (en) | Process for the synthesis of dabigatran and its intermediates | |
KR102295388B1 (en) | A novel synthetic route for the production of optically active diamine derivative and thiazole derivate | |
US20130116441A1 (en) | Intermediates and process for preparing a thrombin specific inhibitor | |
KR20140096571A (en) | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one | |
JP2010510253A (en) | Novel process for the preparation of 4,4 '-(1-methyl-1,2-ethanediyl) -bis- (2,6-piperazinedione) | |
CN116724015A (en) | Process for preparing insecticidal anthranilamides | |
EP1907360B1 (en) | Improved process for the manufacture of flecainide | |
US20140343290A1 (en) | Process for the preparation of atazanavir or its bisulfate salt | |
WO2000073280A1 (en) | Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same | |
US6469172B2 (en) | Process for the preparation of chemical compounds | |
JP2010535185A (en) | Method for producing alfuzosin hydrochloride | |
KR20090027192A (en) | Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane | |
US20120101282A1 (en) | Process for the preparation of nicotinamide derivatives | |
JP4356111B2 (en) | Process for producing N- (2-amino-1,2-dicyanovinyl) formamidine | |
KR101950942B1 (en) | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one | |
WO2006022182A1 (en) | Method for producing 2-(4-methyl-2-phenylpiperazine-1-yl)-3-cyanopiridine | |
KR20220087933A (en) | Method For Producing Diamine Derivative | |
US7214796B2 (en) | Process for production of 1-[2-(benzimidazol-2-yl-thio)ethyl]piperazine or salts thereof | |
JPH08333340A (en) | Production of aminoethylpiperidine derivative | |
JPWO2016171240A1 (en) | Production of dicarboxylic acid compounds | |
JPH0559045A (en) | Production of pyridyloxy derivative | |
US4461728A (en) | Preparation of 4-phenyl-1,3-benzodiazepins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005783707 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005783707 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11988126 Country of ref document: US |